dc.contributor.author | Ghader, F.R. | |
dc.contributor.author | Kousarian, M. | |
dc.contributor.author | Farzin, D. | |
dc.date.accessioned | 2014-06-17T08:05:00Z | |
dc.date.available | 2014-06-17T08:05:00Z | |
dc.date.issued | 2007 | EN |
dc.identifier.issn | 1020-3397 | EN |
dc.identifier.other | http://applications.emro.who.int/emhj/1305/13_5_2007_1053_1059.pdf | EN |
dc.identifier.uri | https://iris.who.int/handle/10665/117346 | |
dc.description | 1053-1059 | EN |
dc.description.abstract | As a means to manage cardiac conditions, we determined the effects of high-dose intravenous [IV] deferoxamine in 15 thalassaemia patients with cardiomyopathy and high ferritin and haemoglobin levels. The patients received IV deferoxamine, 130 mg/kg per day over 10-14 hours [maximum 5 g] for 5 consecutive days. All patients underwent a full evaluation before receiving deferoxamine, and 2 days and 1 month after completing the treatment. Visual and auditory examinations were done to detect any side-effects. After treatment, cardiovascular symptoms decreased considerably and systolic function showed significant improvement, but there was no significant effect on diastolic function, electro-cardiography and physical findings. There were no significant side-effects reported | EN |
dc.language.iso | en | EN |
dc.subject | Deferoxamine | EN |
dc.subject | Thalassemia | EN |
dc.subject | Treatment Outcome | EN |
dc.subject | Cardiomyopathies | EN |
dc.subject | Ferritins | EN |
dc.subject.mesh | Deferoxamine | EN |
dc.title | High-dose deferoxamine treatment [intravenous] for thalassaemia patients with cardiac complications | EN |
dc.relation.ispartofjournal | EMHJ - Eastern Mediterranean Health Journal, 13 (5), 1053-1059, 2007 | |